Advanced search
Publication Cover
The Journal of Maternal-Fetal & Neonatal Medicine Volume 36, 2023 - Issue 1
Submit an article Journal homepage
1,672
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus?

Petr Prasila Department of Infectious Diseases, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech RepublicORCID Iconhttps://orcid.org/0000-0003-1943-9366View further author information
ORCID Icon,
Radek Slehab Department of Epidemiology, University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech RepublicORCID Iconhttps://orcid.org/0000-0001-7359-9147View further author information
ORCID Icon,
Marian Kacerovskyc Department of Obstetrics and Gynecology, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech RepublicORCID Iconhttps://orcid.org/0000-0001-9858-7900View further author information
ORCID Icon &
Pavel Bostikd Institute of Clinical Microbiology, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech RepublicCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2691-6458View further author information
ORCID Icon
Article: 2215377 | Received 18 Jan 2023, Accepted 13 May 2023, Published online: 22 May 2023

References

  • Remington JS, McLeod R, Wilson CB, et al. Toxoplasmosis. In: Remington JS, editor. Infectious diseases of the fetus and newborn infant. 7th ed. Philadelphia: Elsevier Saunders; 2011. p. 918–1041.
  • Montoya JG, Boothryord JC, Kovacs JA, Toxoplasma gondii. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 9th ed. Philadelphia: Elsevier Saunders; 2019. p. 3355–3387.
  • Petersen E, Pollak A, Reiter-Owona I. Recent trends in research on congenital toxoplasmosis. Int J Parasitol. 2001; 31(2):115–144.
  • Geleneky M, Prasil P, Kodym P. [Guidelines for the diagnosis and therapy of toxoplasmosis]: infekce.cz; 2017. [cited 2022 October 21]. Available from: https://www.infekce.cz/DoporToxo17.htm.
  • Dunay IR, Gajurel K, Dhakal R, et al. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31(4):e00057–17.
  • Mandelbrot L, Kieffer F, Wallon M[, et al. Toxoplasmosis in pregnancy: practical management. Gynecol Obstet Fertil Senol. 2021;49(10):782–791.
  • Peyron F, L’ollivier C, Mandelbrot L, et al. Maternal and congenital toxoplasmosis: diagnosis and treatment recommendations of a french multidisciplinary working group. Pathogens. 2019;8(1):24.
  • Peyron F, Mc Leod R, Ajzenberg D, et al. Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches. PLOS Negl Trop Dis. 2017;11(2):e0005222.
  • Borkowski PK, Brydak-Godowska J, Basiak W, et al. Adverse reactions in Antifolate-Treated toxoplasmic retinochoroiditis. Adv Exp Med Biol. 2018;1108:37–48.
  • Caumes E, Bocquet H, Guermonprez G, et al. Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis. Clin Infect Dis. 1995;21(3):656–658.
  • Dannemann B, Mccuthan JA, Israelsi D, et al. Treatment of toxoplasmic encephalitis in patients with AIODS- A randomised trial comparing pyrimethamine plus clindamicin to pyrimethamine plus sulfadiazine. Ann Intern Med. 1992;116(1):33–43.
  • de la Prada Alvarez FJ, Prados Gallardo AM, Tugores Vazquez A, et al. Acute renal failure due to sulfadiazine crystalluria. An Med Interna. 2007; 24(5):235–238.
  • de Sequera P, Albalate M, Hernandez J, et al. Acute renal failure due to sulphadiazine crystalluria in AIDS patients. Postgrad Med J. 1996;72(851):557–558.
  • Crespo M, Quereda C, Pascual J, et al. Patterns of sulfadiazine acute nephrotoxicity. Clin Nephrol. 2000;54(1):68–72.
  • Midskov C. Rapid gas chromatographic determination of pyrimethamine in human plasma and urine. J Chromatogr. 1984;306:388–393.
  • Mouankie JB, Senczuk W, Florek E. Urinary elimination kinetics of pyrimethamine. Eur J Drug Metab Pharmacokinet. 2009; 34(3–4):169–172.
  • Ozturk R, Engin A, Ozaras R, et al. Hyperpigmentation due to pyrimethamine use. J Dermatol. 2002;29(7):443–445.
  • Montoya JG, Laessig K, Fazeli MS, et al. A fresh look at the role of spiramycin in preventing a neglecterd disease: meta-analyses of observational studies. EJMR. 2021;26:143.
  • Mandelbrot L, Kieffer F, Sitta R, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018;219(4):386.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.